Featured Research

from universities, journals, and other organizations

Experimental Drug Derived From Snake Venom Shows Promise In Reversing Effects Of Stroke

Date:
February 5, 1999
Source:
American Heart Association
Summary:
A stroke therapy derived from snake venom? According to researchers, it's not a snake oil story, but instead a possible new way to help people recover from the devastating effects of stroke.

NASHVILLE, Feb. 4 -- A stroke therapy derived from snake venom? According to researchers, it's not a snake oil story, but instead a possible new way to help people recover from the devastating effects of stroke.

Scientists announced the results of a 500-person trial examining the effects of an experimental stroke drug called ANCROD here today at the 24th American Heart Association International Conference on Stroke and Cerebral Circulation.

Researchers found that 42 percent of stroke victims treated with ANCROD within three hours of stroke onset had recovered the physical and mental abilities that they had prior to the stroke.

In comparison, 34 percent of those receiving an inert substance, or placebo, regained their previous faculties. However, stroke patients who received ANCROD were also at a higher risk of bleeding in the brain (5 percent of patients) when compared to those who received the placebo (2 percent).

ANCROD is not yet approved by the Food and Drug Administration for stroke treatment. Tissue plasminogen activator (TPA) is the only FDA-approved acute stroke treatment.

ANCROD is derived from the venom of a pit viper snake. Researchers discovered that in people who were bitten by the snake, blood failed to clot. Based on that observation, the venom was utilized as an anticoagulant, helping blood flow more freely through vessels.

"Like clot-dissolving drugs TPA and urokinase, the goal was for ANCROD to be administered within three hours of stroke onset," says the study's lead author, David Sherman, M.D. "Also, none of these three drugs are for use in patients who have hemorrhagic strokes, caused by a burst or leaking blood vessel in the brain."

There are sharp contrasts between the treatments, however, says Sherman.

TPA is administered in a single-dose, hour-long injection and results can be seen soon thereafter. ANCROD is given intravenously through a catheter over a 3-to-5 day span in the hospital. While TPA dissolves the clots causing the most common type of stroke, ANCROD lowers the level of fibrinogen in the bloodstream.

Fibrinogen is a clotting factor that is produced naturally by the body. It can help form clots that can in turn block blood flow to the brain, resulting in a stroke. ANCROD improves the bloods viscosity, a measurement of how well it flows through blood vessels.

"We found that patients who had their fibrinogen levels lowered promptly, within 6 hours, and maintained in the target range after treatment had the best response to the treatment," says Sherman, professor and chief, division of neurology, University of Texas Health Science Center, San Antonio.

The initial amount of ANCROD administered is determined by the patients blood fibrinogen level and body weight.

The additional amounts of ANCROD administered is adjusted based on the amount of fibrinogen in the blood, which is regularly monitored for 3-to-5 days during hospitalization, according to Sherman. By keeping the fibrinogen levels between 40-70 milligrams per deciliter of blood, Sherman says it's possible to reverse the effects of the initial stroke, minimize the bleeding risk and protect against a recurrent stroke during therapy.

"What I envision if ANCROD is approved is that the physician would have the option of using either TPA or ANCROD, based on what would be best for that particular patient," says Sherman. "Overall, TPA has been shown to be a little bit more effective than ANCROD, but it also carries a little bit more danger with the possibility of bleeding in the brain. It's also easier to use -- one shot, one hour and youre done."

"With ANCROD, you're treating someone for 3 to 5 days and making sure their fibrinogen levels dont get too low or too high. There's more of a user-friendliness with ANCROD in the sense that youre able to monitor the patient more closely as you move forward with the treatment."

In the study, patients were treated between 3-to-5 days and then followed up at 3 months post-stroke; their progress was measured by various tests to determine neurological damage and ability to function in a normal manner.

"We think that its probably going to turn out to be safer than TPA in terms of risk of bleeding," says Sherman. "With the new therapy, the effects of the drug are sustained for five days instead of an hour or two, without increasing the bleeding risk over time."

The major risk in using clot-busting drugs is bleeding, or hemorrhage, in the brain.

Sherman says that ANCROD should not be considered a clot-busting therapy like TPA or urokinase, even though it does have similar properties.

"It's given through an IV infusion, so in that sense its similar to TPA," says Sherman. "TPA is usually an hour-long infusion while ANCROD is continuous over three days so you dont have the dramatic changes in coagulation that you can get with other types of clot-dissolving therapy."


Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.


Cite This Page:

American Heart Association. "Experimental Drug Derived From Snake Venom Shows Promise In Reversing Effects Of Stroke." ScienceDaily. ScienceDaily, 5 February 1999. <www.sciencedaily.com/releases/1999/02/990205085135.htm>.
American Heart Association. (1999, February 5). Experimental Drug Derived From Snake Venom Shows Promise In Reversing Effects Of Stroke. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/1999/02/990205085135.htm
American Heart Association. "Experimental Drug Derived From Snake Venom Shows Promise In Reversing Effects Of Stroke." ScienceDaily. www.sciencedaily.com/releases/1999/02/990205085135.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) — The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) — An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) — Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Fauci: Ebola Protocols to Focus on Training

Fauci: Ebola Protocols to Focus on Training

AP (Oct. 20, 2014) — Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, says he expects revised CDC protocols on Ebola to focus on training, observation and ensuring health care workers are more protected. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins